Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)

ClinicalTrials.gov ID: NCT03449134

Public ClinicalTrials.gov record NCT03449134. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 3:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants With Chronic Cough (PN027)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main objectives of this study will be to evaluate the efficacy of gefapixant in reducing cough frequency as measured over a 24-hour period at Week 12, and to evaluate the safety and tolerability of gefapixant. The primary hypothesis is that at least one gefapixant dose is superior to placebo in reducing coughs per hour (over 24 hours) at Week 12.

Study identification

NCT ID
NCT03449134
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Enrollment
732 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 13, 2018
Primary completion
Jun 4, 2020
Completion
Aug 16, 2020
Last update posted
Jun 15, 2021

2018 – 2020

United States locations

U.S. sites
27
U.S. states
15
U.S. cities
26
Facility City State ZIP Site status
Research Solutions of Arizona PC ( Site 0036) Litchfield Park Arizona 85340
Medical Research of AZ ( Site 0060) Scottsdale Arizona 85251
Biosolutions Clinical Research Center ( Site 0070) La Mesa California 91942
Center for Clinical Trials, LLC ( Site 0059) Paramount California 90723
Sher Allergy Specialists/Center For Cough ( Site 0078) Largo Florida 33778
Well Pharma Medical Research, Corp. ( Site 0093) Miami Florida 33143
Florida Pulmonary Research Institute, LLC ( Site 0019) Winter Park Florida 32789
Midwest Allergy Sinus Asthma, SC ( Site 0081) Normal Illinois 61761
Cotton-O'Neil Clinical Research Center ( Site 0052) Topeka Kansas 66606
BreatheAmerica Inc ( Site 0048) Shreveport Louisiana 71106
Clinical Research Institute LLC ( Site 0004) Minneapolis Minnesota 55402
The Center for Pharmaceutical Research PC ( Site 0016) Kansas City Missouri 64114
American Health Research ( Site 0082) Charlotte North Carolina 28207
Clinical Research of Gastonia ( Site 0043) Gastonia North Carolina 28054
Bernstein Clinical Research Center, LLC ( Site 0005) Cincinnati Ohio 45231
Vital Prospects Clinical Research Institute, PC ( Site 0037) Tulsa Oklahoma 74136
Asthma Nasal Disease & Allergy Research Center of New England ( Site 0075) East Providence Rhode Island 02914
Sirius Clinical Research, LLC ( Site 0102) Austin Texas 78759
Pharmaceutical Research & Consulting, Inc. ( Site 0029) Dallas Texas 75231
Mainland Medical Research Institute ( Site 0003) Dickinson Texas 77539
Diagnostics Research Group ( Site 0035) San Antonio Texas 78229
Allergy & Asthma Center ( Site 0001) Waco Texas 76712
Intermountain Clinical Research ( Site 0033) Draper Utah 84020
Charlottesville Medical Research Center, LLC ( Site 0006) Charlottesville Virginia 22911
Pulmonary Associates of Richmond Inc. ( Site 0101) Richmond Virginia 23225
National Clinical Research-Richmond, Inc. ( Site 0073) Richmond Virginia 23294
Lung and Sleep Specialists ( Site 0091) Williamsburg Virginia 23188

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 129 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03449134, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 15, 2021 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03449134 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →